Kronos Bio Inc

40 articles with Kronos Bio Inc

• 

  Top Biotech Licensing Deals of Q1 2023

  3/30/2023

  There have already been several big biotech licensing deals in Q1. See inside for some of this quarter's biggest licensing deals — from the surprising and pivotal to the lucrative and consequential.

• Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results

  3/15/2023

  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and fourth-quarter and full-year 2022 financial results.

• Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference

  2/28/2023

  Kronos Bio, Inc. announced participation in the 43rd Annual Cowen Health Care Conference, taking place March 6-8, 2023, in Boston, Massachusetts.

• Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology

  1/9/2023

  Kronos Bio, Inc. (Nasdaq: KRON) announced today that it has entered into a discovery collaboration in the field of oncology with Genentech, a member of the Roche Group, focused on discovering and developing small-molecule drugs that modulate transcription factor targets selected by Genentech.

• Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting

  12/11/2022

  Kronos Bio, Inc. is presenting preclinical data that demonstrate anti-leukemic activity of the investigational spleen tyrosine kinase inhibitor, lanraplenib, in combination with multiple targeted agents in patient-derived cell isolates and cell lines at the 64th American Society of Hematology Annual Meeting & Exposition in New Orleans.

• Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial

  12/7/2022

  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that data from the ongoing dose-escalation stage of its Phase 1/2 clinical trial of KB-0742, the company’s cyclin dependent kinase 9 (CDK9) inhibitor being developed to treat MYC-amplified and transcriptionally addicted solid tumors, support a recommended Phase 2 dose (RP2D) of 60 mg.

• Kronos Bio Announces Participation in Upcoming Investor Conferences - November 22, 2022

  11/22/2022

  Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, announced that members of the management team will participate in fireside chats at the following investor conferences:

• Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results

  11/8/2022

  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and third-quarter 2022 financial results.

• Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742

  11/8/2022

  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the prioritization of its clinical portfolio to focus on the development of its next generation SYK inhibitor, lanraplenib, and its CDK9 inhibitor, KB-0742.

• Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022

  10/12/2022

  Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, announced that it will present preclinical data in a poster at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

• Kronos Bio Announces Participation in H.C. Wainwright 24th Annual Global Investment Conference

  9/6/2022

  Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer and other serious diseases, announced participation in the H.C. Wainwright 24th Annual Global Investment Conference.

• Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia

  8/22/2022

  Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that the first patient has been dosed in a Phase 1b/2 clinical trial of lanraplenib in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML).

• Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML

  8/16/2022

  Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of diagnostic kits and services for oncology, announced their agreement to develop a companion diagnostic for use with Kronos Bio’s investigational therapy, entospletinib.

• Kronos Bio Reports Recent Business Progress and Second-Quarter 2022 Financial Results

  8/4/2022

  Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer and other serious diseases, reported recent business progress and second-quarter 2022 financial results.

• Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress

  6/10/2022

  Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer and other serious diseases, will present preclinical data from studies of the company’s two novel investigational spleen tyrosine kinase inhibitors, entospletinib and lanraplenib.

• Kronos Bio Announces Participation in Upcoming Investor Conferences - June 01, 2022

  6/1/2022

  Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer and other serious diseases, announced that President and Chief Executive Officer Norbert Bischofberger, Ph.D., will participate in fireside chats at the following investor conferences:

• Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference

  5/17/2022

  Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer and other serious diseases, announced participation in the H.C. Wainwright Global Investment Conference.

• Kronos Bio’s Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress

  5/12/2022

  Kronos Bio, Inc. announced that its two novel investigational spleen tyrosine kinase inhibitors, entospletinib and lanraplenib, will be featured in poster presentations at the European Hematology Association 2022 Congress, being held June 9-12 in Vienna.

• Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results

  5/4/2022

  Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer and other serious diseases, reported recent business progress and first quarter 2022 financial results.

• Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR

  4/8/2022

  Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer and other serious diseases, shared preclinical data on its internally discovered, highly selective, oral cyclin dependent kinase 9 inhibitor, KB-0742, adding to evidence that the compound has the potential to treat certain MYC-amplified and transcriptionally addicted solid tumors.